Metrics to compare | GX1 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGX1PeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.1x | −6.6x | −0.3x | |
PEG Ratio | −0.24 | 0.00 | 0.00 | |
Price / Book | 2.6x | 2.9x | 2.6x | |
Price / LTM Sales | 8.0x | 4.3x | 3.0x | |
Upside (Analyst Target) | - | 74.5% | 58.2% | |
Fair Value Upside | Unlock | 14.2% | 7.5% | Unlock |
genXone S.A., a biotechnology company, provides nucleic acid sequencing services based on nanopore sequencing technology in Poland and internationally. The company offers whole genome, metagenome, shotgun metagenomic, plasmid DNA, and transcriptome sequencing services, as well as bioinformatic analysis. It also provides nucleic acid isolation; molecular diagnostics laboratory; and operates in the field of molecular genetics and bioinformatics. In addition, the company develops solutions in the form of laboratory protocols, as well as bioinformatics tools, scripts, and algorithms enabling the use of nanopore sequencing in various areas of science and business, including genetic diagnostics, food industry, veterinary medicine, and agriculture. genXone S.A. was incorporated in 2018 and is headquartered in Suchy Las, Poland.